Sweden
· Delayed Price · Currency is SEK Initiator Pharma Company Description
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system.
Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indication in severe neuropathic pain, and trigeminal neuralgia.
The company also developing IP2017, a proprietary triple reuptake inhibitor; and IP2016, a preclinical development for the treatment of depression.
Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Claus Olesen |
Contact Details
Address: Ole Maaloes vej 3 Copenhagen, 2200 | |
| Phone | 45 61 26 00 35 |
| Website | initiatorpharma.com |
Stock Details
| Ticker Symbol | INIT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0060775872 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Claus Elsborg Olesen | Co-Founder, Chief Executive Officer and Director |
| Dr. Dan Peters | Co-Founder and Chief Technology Officer |
| Prof. Ulf Simonsen Ph.D. | Co-Founder, CMO and CSO |
| Dr. Mikael Thomsen M.Sc., Ph.D. | Co-Founder and Chief Development Officer |
| Dr. Torgeir Vaage Ph.D. | Chief Financial Officer |
| Dr. Allan Wehnert | Senior Vice President of Clinical and Research & Development Strategy and Portfolio Management |
| Susanne Thomsen | Head of Clin Ops |
| Rene Egebro M.Sc. | Head of CMC |